BLUEBIRD BIO INC (BLUE) Stock Price, Forecast & Analysis
USA - NASDAQ:BLUE - US09609G2093 - Common Stock
BLUE Key Statistics, Chart & Performance
The current stock price of BLUE is 4.97 USD. In the past month the price increased by 22.72%. In the past year, price decreased by -72.49%.
BLUE Latest News, Press Relases and Analysis
BLUE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About BLUE
Company Profile
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. The company is headquartered in Somerville, Massachusetts and currently employs 248 full-time employees. The company went IPO on 2013-06-19. The firm is focused on researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The company markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA is used for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).
Company Info
BLUEBIRD BIO INC
455 Grand Union Boulevard
Somerville MASSACHUSETTS 02142 US
CEO: Nick Leschly
Employees: 248
Phone: 13394999300
BLUEBIRD BIO INC / BLUE FAQ
What does BLUE do?
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. The company is headquartered in Somerville, Massachusetts and currently employs 248 full-time employees. The company went IPO on 2013-06-19. The firm is focused on researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The company markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA is used for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).
What is the current price of BLUE stock?
The current stock price of BLUE is 4.97 USD.
Does BLUEBIRD BIO INC pay dividends?
BLUE does not pay a dividend.
What is the ChartMill technical and fundamental rating of BLUE stock?
BLUE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for BLUE stock?
10 analysts have analysed BLUE and the average price target is 8.84 USD. This implies a price increase of 77.87% is expected in the next year compared to the current price of 4.97.
Is BLUEBIRD BIO INC (BLUE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BLUE.
Can you provide the ownership details for BLUE stock?
You can find the ownership structure of BLUEBIRD BIO INC (BLUE) on the Ownership tab.
BLUE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BLUE. When comparing the yearly performance of all stocks, BLUE is a bad performer in the overall market: 88.09% of all stocks are doing better.
BLUE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BLUE. BLUE may be in some trouble as it scores bad on both profitability and health.
BLUE Financial Highlights
Over the last trailing twelve months BLUE reported a non-GAAP Earnings per Share(EPS) of -20.53. The EPS increased by 58.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BLUE Forecast & Estimates
10 analysts have analysed BLUE and the average price target is 8.84 USD. This implies a price increase of 77.87% is expected in the next year compared to the current price of 4.97.
For the next year, analysts expect an EPS growth of 52.54% and a revenue growth 199.26% for BLUE